DeepLife appoints Ivan Griffin and Jakob E. Larsen to its Advisory Board.

We are pleased to welcome Ivan Griffin, co-founder of BenevolentAI, and Jakob E. Larsen, who spent 15 years at Novo Nordisk leading target discovery efforts, as advisors to DeepLife.

Ivan brings nearly two decades of experience across life sciences, technology, investment and company building. Jakob adds more than a decade of global pharmaceutical R&D and strategic experience from Novo Nordisk, advancing early discovery programs by applying innovative science and digital approaches. 

Their complementary expertise will support DeepLife as we continue to advance TwinCell and apply causal models of human cells to target identification and indication expansion.

We are proud to welcome Ivan and Jakob to our Advisory Board and look forward to working closely with them as DeepLife continues to grow.